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Abstract: This study examined the role of endothelin-1 (ET-1) in recruiting inﬂ  ammatory cells 
to the lung after induction of injury with either lipopolysaccharide (LPS) or cigarette smoke. 
Hamsters injected with either ET-1 or its precursor peptide (Big ET-1) prior to treatment with 
LPS or cigarette smoke had markedly increased concentrations of neutrophils in bronchoalveolar 
lavage ﬂ  uid (BALF) despite a reduction in total numbers of BALF leukocytes. Furthermore, the 
effect of ET-1 on smoke-exposed animals was reversed by addition of an endothelin-A receptor 
antagonist. These results are consistent with preferential recruitment of neutrophils by ET-1, 
and suggest that inhibition of this proinﬂ  ammatory mediator may decrease acute pulmonary 
inﬂ  ammation associated with cigarette smoke and other pulmonary toxins.
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Introduction
Endothelin-1 (ET-1) is a proinﬂ  ammatory mediator that is formed by the conversion 
of a 39-amino acid precursor peptide, Big ET-1, to the 21-amino acid peptide, ET-1 
(Hisaki et al 1994; Laporte and Sirois 1997; Fagan et al 2001). It activates neutrophils 
and induces the release of a variety of cytokines by monocytes (Teder and Noble 2000). 
In addition, ET-1 is a potent vasoconstrictor that plays an important role in ischemic 
injury (Hassan et al 1997; Aguilar et al 2000; Park and Thornhill 2001).
Previously, this laboratory has shown that inhibition of ET-1 activity with either 
phosphoramidon (an endothelin-converting enzyme inhibitor) or an endothelin 
receptor antagonist markedly reduces lipopolysaccharide (LPS)-induced inﬂ  ux of 
neutrophils into the lung (Bhavsar et al 2008). However, it remains to be determined 
whether ET-1 acts selectively on neutrophils or has a wider role in the recruitment 
of leukocytes.
To address this question, we examined the effect of exogenously administered ET-1 
or its precursor peptide, Big ET-1, on LPS-induced inﬂ  ammation in hamster lungs. 
Five hours after LPS instillation (when the inﬂ  ammatory reaction was maximal), the 
animals were sacriﬁ  ced and bronchoalveolar lavage ﬂ  uid (BALF) leukocytes were 
examined. The results indicate that both ET-1 and Big ET-1 induce a preferential 
inﬂ  ux of neutrophils into the lung.
Since cigarette smoke contains signiﬁ  cant amounts of LPS (Hasday et al 1999; 
Larsson et 2004), we also investigated the possibility that ET-1 might produce a similar 
outcome in smoke-exposed animals. Measurement of BALF leukocytes again dem-
onstrated a selective recruitment of neutrophils by ET-1. Furthermore, this effect was 
reversed by concomitant treatment with an endothelin receptor antagonist, suggesting 
a possible role for this type of agent in reducing smoke-related lung injury.International Journal of COPD 2008:3(3) 478
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Methods
Experimental design
LPS model
Female Syrian hamsters, weighing approximately 100 g 
each, were divided into 4 groups as follows: Group 1 was 
treated intraperitoneally (IP) with 20 μg bovine “big” ET-1 
(Sigma-Aldrich, St Louis, MO) in 0.2 mL PBS, followed 
60 min later by 10 μg intratracheal (IT) LPS (Sigma-Aldrich) 
in 0.2 mL PBS; Group 2 was treated IP with 20 μg of human 
ET-1 (Sigma-Aldrich) in 0.2 mL PBS, followed 60 min later 
by 10 μg IT LPS in 0.2 mL PBS; Group 3 was treated IP 
with 0.2 mL PBS, followed 60 min later by 10 μg IT LPS 
in 0.2 mL PBS; Group 4 was treated IP with 0.2 mL PBS, 
followed 60 min later by 0.2 mL IT PBS. All animals were 
sacriﬁ  ced 5 h after LPS instillation, when the pulmonary 
inﬂ  ammatory reaction was maximal, and both the total num-
ber of BALF leukocytes and percentage of BALF neutrophils 
were measured (Nadkarni et al 2005). The protocol was 
approved by the institutional animal care committee.
Cigarette smoke model
Female Syrian hamsters, weighing approximately 100 g each, 
were divided into 4 groups as follows: Group 1 was treated 
IP with: 1) 500 μg of HJP272, a novel endothelin-A receptor 
antagonist, in 0.5 mL Na2CO3 and 2) 5 μg ET-1 in 0.25 mL PBS 
60 min later, followed immediately by exposure to cigarette 
smoke for 2 h. This regimen was continued for 3 consecutive 
days; Group 2 was treated IP with: 1) 0.5 mL Na2CO3 and 2) 
5 μg ET-1 in 0.25 mL PBS 60 min later, followed immediately 
by exposure to cigarette smoke for 3 consecutive days as per 
Group 1; Group 3 was treated IP with: 1) 0.5 mL Na2CO3 and 2) 
0.25 mL PBS 60 min later, followed immediately by exposure 
to cigarette smoke for 3 consecutive days as per Group 1; 
Group 4 was treated IP with: 1) 0.5 mL Na2CO3 and 2) 0.25 mL 
PBS 60 min later, followed by exposure to room air for 3 days. 
All animals were sacriﬁ  ced 24 h after completing the smoke 
exposure regimen to maximize the neutrophil population in 
the lung, and both the total number of BALF leukocytes and 
percentage of BALF neutrophils were measured (van der Vaart 
et al 2004). The protocol was approved by the institutional 
animal care committee.
Treatment with LPS
Prior to LPS instillation, animals were anesthetized by IP injec-
tion of pentobarbital (90 mg/kg). LPS was then delivered via 
the trachea with a 27-gauge needle attached to a 1-mL syringe. 
After instillation, the incision was closed with metal clips. The 
LPS used in these experiments was serotype O26:B6, obtained 
from American Type Culture Collection no. 12795; with short 
chain-length approximating that of mutant rough strain LPS.
Exposure to cigarette smoke
Animals were placed in a 70 × 48 × 38 cm chamber and passively 
exposed to cigarette smoke for 2 h per day for 3 consecutive 
days. The smoke was produced by a TE-10 smoking machine 
(Teague Enterprises, Davis, CA) that simultaneously burned 
2 ﬁ  ltered research-grade cigarettes (type 2R4F, University of 
Kentucky). Smoke from both the ﬁ  ltered and burning ends 
of the cigarette were collected, then mixed together with air 
in a separate chamber, thus simulating second-hand smoke 
exposure. Each cigarette was puffed once per min for 2 sec at 
a ﬂ  ow rate of 1.05 LPM, yielding 35 mL of smoke. This cycle 
was repeated 9 times before ejecting the cigarette and loading 
a new one. Proper ﬂ  ow rate was maintained by a vacuum pump 
that established negative pressure at the exhaust port. Total 
smoke particulates averaged 87 mg per cubic meter.
Bronchoalveolar lavage
After euthanasia with i.p. pentobarbital, lungs were lavaged 
3× with normal saline, using 1 aliquot of 3 mL followed by 2 
aliquots of 2 mL each. The lavage ﬂ  uid was centrifuged and 
the cells were resuspended in 1.0 mL PBS. Total leukocyte 
counts were determined with a hemocytometer. Differential 
counts were obtained on cytospin preparations treated with 
Wright’s stain.
Statistical analysis
The Newman-Keuls multiple comparisons test was used 
to determine statistically signiﬁ  cant differences (p < 0.05) 
among the treatment groups.
Results
LPS model
Treatment with either ET-1 or Big ET-1 prior to LPS sig-
niﬁ  cantly increased the percentage of BALF neutrophils. As 
shown in Figure 1, animals receiving ET-1 or Big ET-1 had 
89% and 80% neutrophils respectively, compared to 5% and 
1% for controls treated only with intratracheal LPS or PBS, 
respectively. The remaining BALF cells in all treatment 
groups were predominantly macrophages.
Conversely, both ET-1 and Big ET-1 signiﬁ  cantly low-
ered total BALF leukocytes in LPS-treated hamsters. Animals 
receiving ET-1 or Big ET-1 had 2.1 × 104 and 2.8 × 104 cells 
respectively, compared to 5.2 × 104 cells for those treated 
with intratracheal LPS alone (Figure 1). Controls given 
intratracheal PBS alone had 1.3 × 103 cells.International Journal of COPD 2008:3(3) 479
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Cigarette smoke model
Treatment with ET-1 prior to exposure to cigarette smoke 
signiﬁ  cantly increased the percentage of BALF neutro-
phils. As shown in Figure 2, hamsters receiving ET-1 had 
46% neutrophils compared to 18% and 1% for controls 
treated only with cigarette smoke or ET-1 and room air, 
respectively. Furthermore, pretreatment with the ET-A 
receptor antagonist, HJP272, reversed this effect (Figure 2), 
lowering the percentage of BALF neutrophils to less than 
that of controls treated with cigarette smoke alone. The 
remaining BALF cells in all treatment groups were predomi-
nantly macrophages.
With regard to total BALF leukocytes, animals treated 
with either ET-1 or ET-1 plus HJP272 had fewer cells 
Figure 1 (Upper) Animals receiving ET-1 or Big ET-1 prior to LPS had a signiﬁ  cantly 
higher percentage of BALF neutrophils than controls treated only with intratracheal 
LPS or PBS (N = 3 for all groups). (Lower) Animals receiving ET-1 or Big ET-1 prior 
to LPS had signiﬁ  cantly fewer total BALF leukocytes than controls treated with 
intratracheal LPS (N = 3 for all groups). For both graphs, T-bars indicate standard 
error of the mean (SEM).
(1.7 × 104 and 1.3 × 104, respectively) than controls treated 
with cigarette smoke alone (2.0 × 104), but the differ-
ences among the groups were not statistically signiﬁ  cant 
(Figure 2).
Discussion
The results of these experiments are consistent with selective 
recruitment of neutrophils by ET-1, and suggest that this 
mediator may play an important role in modulating the 
pulmonary inﬂ  ammatory response. The level of ET-1 synthesis 
could determine whether the inﬂ  ammatory cell population is 
predominantly composed of neutrophils or monocytes. Such 
variation in the nature of the inﬂ  ammatory response could have 
important implications for the type and extent of lung damage 
resulting from exposure to different pulmonary toxins.
An example of the potential importance of modulating 
the pulmonary response to injury is seen in a previous study 
from this laboratory in which LPS and cigarette smoke were 
combined to produce a much greater inﬂ  ammatory response 
than that seen with either agent alone (Kulkarni et al 2007). 
Whereas LPS and cigarette smoke separately produced a 
predominantly monocytic inﬂ  ammatory cell inﬂ  ux into the 
lung, their combination resulted in a very large increase in 
recruitment of neutrophils to the lung, with concomitant 
enhancement of histopathological changes and markedly 
elevated alveolar septal cell apoptosis.
At the time this study was performed, the underlying 
mechanism for this transformation of the inﬂ  ammatory 
response remained obscure. However, it is now possible to 
speculate that the dramatic rise in the neutrophil population 
could be related to enhanced synthesis of ET-1, whose effects 
might become much greater when a certain threshold level 
is achieved.
Of the two agents involved in the aforementioned study, 
LPS may be more effective in increasing ET-1 activity. Stud-
ies have shown that LPS stimulates the synthesis of ET-1 
both in vivo and in vitro (Ohta et al 1990; Forni et al 2005; 
Zaedi et al 2006). Furthermore, the use of a nonselective 
endothelin receptor antagonist, tezosentan, has been shown 
to limit various hemodynamic abnormalities associated with 
endotoxemia, including pulmonary edema (Kuklin et al 2004; 
Rossi et al 2004).
The extent to which cigarette smoke enhances ET-1 syn-
thesis may be directly related to LPS. In one study, cigarette 
smoke was found to contain 120 times the level of LPS 
associated with smoke-free indoor air (Larsson et al 2004). 
While this quantity of LPS may be small in comparison to that 
employed in the proposed experiments, it may nevertheless 
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have a cumulative effect, resulting in the development of low-
grade pulmonary inﬂ  ammation that could cause signiﬁ  cant 
lung damage over time.
While the mechanism responsible for the speciﬁ  c effect 
on neutrophils remains unclear, it may involve upregulation 
of ICAM-1, which facilitates their adhesion to vascular endo-
thelium (Zhang et al 2006). Alternatively, ET-1 could increase 
neutrophil expression of CXCR2, a cell-surface receptor that 
binds interleukin-8, a potent activator of these cells (DiVietro 
et al 2001; Reutershan et al 2006). Either of these processes 
could be enhanced by the fact that ET-1 can change the F-actin 
content of neutrophils, thereby promoting their sequestration 
in pulmonary microvessels (Sato et al 2000).
In the current studies, treatment with an ET-A recep-
tor antagonist reversed the effect of ET-1 on neutrophil 
recruitment to the lung. This ﬁ  nding may reﬂ  ect an impaired 
ability of these cells to adhere to pulmonary vascular endo-
thelium. Further support for this concept is found in stud-
ies of inﬂ  ammatory bowel disease, where treatment with 
the nonselective endothelin receptor antagonist, bosentan, 
resulted in markedly reduced attachment of neutrophils to 
colonic submucosal venules (Anthoni et al 2006).
With regard to the cellular composition of inﬂ  ammatory 
reactions, there is increasing evidence that ET-1 confers a 
selective advantage on neutrophils, allowing them to popu-
late the lung at the expense of other inﬂ  ammatory cells. 
Such a process might have important implications for the 
treatment of inﬂ  ammatory lung disorders, including COPD. 
Reducing ET-1 activity with endothelin receptor antagonists 
and other agents could potentially decrease neutrophil-
derived enzymes and oxidants in the lung, thereby slowing 
the progression of lung injury.
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